These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
850 related items for PubMed ID: 1902487
1. Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders. Filicori M, Flamigni C, Meriggiola MC, Ferrari P, Michelacci L, Campaniello E, Valdiserri A, Cognigni G. J Clin Endocrinol Metab; 1991 May; 72(5):965-72. PubMed ID: 1902487 [Abstract] [Full Text] [Related]
2. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management. Filicori M, Flamigni C, Campaniello E, Valdiserri A, Ferrari P, Meriggiola MC, Michelacci L, Pareschi A. J Clin Endocrinol Metab; 1989 Oct; 69(4):825-31. PubMed ID: 2506216 [Abstract] [Full Text] [Related]
3. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome. Gill S, Taylor AE, Martin KA, Welt CK, Adams JM, Hall JE. J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835 [Abstract] [Full Text] [Related]
4. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH. Filicori M, Campaniello E, Michelacci L, Pareschi A, Ferrari P, Bolelli G, Flamigni C. J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511 [Abstract] [Full Text] [Related]
10. Exaggerated free alpha-subunit levels during pulsatile gonadotropin-releasing hormone replacement in women with idiopathic hypogonadotropic hypogonadism. Lavoie HB, Martin KA, Taylor E, Crowley WF, Hall JE. J Clin Endocrinol Metab; 1998 Jan; 83(1):241-7. PubMed ID: 9435449 [Abstract] [Full Text] [Related]
17. Induction of ovulation in clomiphene-resistant polycystic ovary syndrome with pulsatile GnRH. Tan SL, Farhi J, Homburg R, Jacobs HS. Obstet Gynecol; 1996 Aug; 88(2):221-6. PubMed ID: 8692506 [Abstract] [Full Text] [Related]
18. Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: a pilot prospective study. Fulghesu AM, Ciampelli M, Belosi C, Apa R, Guido M, Caruso A, Mancuso S, Lanzone A. J Endocrinol Invest; 2001 Aug; 24(7):483-90. PubMed ID: 11508781 [Abstract] [Full Text] [Related]
19. Pulsatile gonadotropin-releasing hormone therapy for ovulatory disorders. Santoro N, Elzahr D. Clin Obstet Gynecol; 1993 Sep; 36(3):727-36. PubMed ID: 8403619 [Abstract] [Full Text] [Related]
20. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease. Blankstein J, Rabinovici J, Goldenberg M, Shaley J, Mehta A, Serr DM, Mashiach S. J Clin Endocrinol Metab; 1987 Dec; 65(6):1164-7. PubMed ID: 3119650 [Abstract] [Full Text] [Related] Page: [Next] [New Search]